Abstract
Objective: This study aimed to evaluate the cost‐effectiveness of a mometasone steroid‐eluting sinus implant compared to a nonsteroid‐eluting sinus implant following endoscopic sinus surgery (ESS) for chronic rhinosinusitis.Study Design: Economic evaluation using a decision tree model.Setting: Academic and nonacademic otolaryngology practices.Subjects: Patients with refractory chronic rhinosinusitis undergoing ESS.Methods: The economic perspective was the health care third party payer. Effectiveness and probability data were obtained from a single meta‐analysis of 2 randomized, double‐blind, controlled trials. Costs were obtained from the Centers for Medicare & Medicaid Services database and wholesale pharmaceutical pricing. Multiple sensitivity analyses were performed including a probabilistic sensitivity analysis. Comparative treatment groups were (1) placement of the mometasone steroid‐eluting sinus implant following ESS and (2) placement of a nonsteroid‐eluting implant following ESS. The primary outcome was cost per postoperative intervention avoided within 60 days after ESS.Results: The mean cost for the steroid‐eluting and nonsteroid‐eluting sinus implant strategies were $1,572.91 and $365.18, respectively. The steroid‐eluting strategy incremental cost‐effectiveness ratio was $5,489.68. The sensitivity analysis demonstrated a 74.3%, 87.2%, and 90.5% certainty that the steroid‐eluting implant strategy is cost‐effective at willingness‐to‐pay thresholds of $10,000, $25,000, and $50,000, respectively.Conclusion: Results from this economic evaluation suggest that placement of a mometasone steroid‐eluting sinus implant into the ethmoid cavity following ESS for refractory chronic rhinosinusitis is a cost‐effective intervention for preventing a postoperative intervention within 60 days after surgery.
Funding Information
  • National Institutes of Health

This publication has 16 references indexed in Scilit: